Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations

• DOI: 10.1099/vir.0.023242-0
• Publication Date: 2010-12-16T00:17:27Z
• Authors: A. D. Cristillo; M. G. Ferrari; L. Hudacik; B. Lewis; L. Galmin; B. Bowen; D. Thompson; N. Petrovsky; P. Markham; R. Pal
• Keywords: Priming (agriculture); HIV vaccine; Mucosal immunology; Heterologous

As sexual transmission of human immunodeficiency virus-1 (HIV-1) occurs via the mucosa, an ideal HIV-1 vaccine should induce both mucosal and systemic immunity. We therefore sought to evaluate induction responses using a DNA env prime–gp120 protein boost approach in which sequential nasal parenteral administration was performed with two novel carbohydrate-based adjuvants. These adjuvants, Advax-M Advax-P, were specifically designed for immune enhancement, respectively. Murine intranasal immunization gp120/Advax-M adjuvant elicited gp120-specific IgA serum secretions that markedly enhanced by priming. Boosting DNA-primed mice gp120/Advax-P intramuscular immunization, or vice versa, persistent IgA, IgG memory T- B-cell responses. Induction homologous, but not heterologous, neutralizing activity noted sera all immunized groups. While confirmation efficacy is required challenge studies non-human primates, these results suggest combination priming boosting, appropriate could generate strong immunity may block infection.